	US 12,467,090 B2
	Method for assessing risk of cutaneous adverse drug reactions caused by epidermal growth factor receptor inhibitors, detection kit thereof, and use thereof
Wen-Hung Chung, Taoyuan (TW); Shuen-Iu Hung, Taoyuan (TW); Chun-Bing Chen, Taoyuan (TW); Chun-Wei Lu, Taoyuan (TW); and Chuang-Wei Wang, Taoyuan (TW)
Assigned to CHANG GUNG MEMORIAL HOSPITAL, LINKOU, Taoyuan (TW)
Appl. No. 17/634,283
Filed by CHANG GUNG MEMORIAL HOSPITAL, LINKOU, Taoyuan (TW)
PCT Filed Aug. 16, 2019, PCT No. PCT/CN2019/100908 § 371(c)(1), (2) Date Feb. 10, 2022, PCT Pub. No. WO2021/030925, PCT Pub. Date Feb. 25, 2021.
Prior Publication US 2023/0076745 A1, Mar. 9, 2023
Int. Cl. C12Q 1/6881 (2018.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01)

CPC C12Q 1/6881 (2013.01) [C12Q 1/6883 (2013.01); G01N 33/6893 (2013.01); C12Q 2600/118 (2013.01); G01N 2800/50 (2013.01); G01N 2800/56 (2013.01)]

13 Claims

1. A method for treating a cutaneous adverse drug reaction induced by an epidermal growth factor receptor inhibitor (EGFRI) in a patient in need thereof, comprising the following steps:

(a) obtaining a sample from the patient, wherein the patient exhibits one or more symptoms of the cutaneous adverse drug reaction induced by EGFRI or at risk of developing the cutaneous adverse drug reaction induced by EGFRI,

(b) detecting the presence of the following alleles from the sample of the patient:

HLA-B*5101;

HLA-B*5102; or

HLA-B*5101 and HLA-B*5102,

(c) identifying the patient as having the cutaneous adverse drug reaction or at risk of developing the cutaneous adverse drug reaction induced by EGFRI if at least one of the alleles in step (b) is present in the sample of the patient; and thereafter

(d) administering a drug to treat the cutaneous adverse drug reaction induced by EGFRI.